GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Ending Cash Position

Medy-Tox (XKRX:086900) Ending Cash Position : ₩36,618 Mil (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Medy-Tox Ending Cash Position?

Medy-Tox's Ending Cash Position for the quarter that ended in Mar. 2024 was ₩36,618 Mil.

Medy-Tox's quarterly Ending Cash Position declined from Sep. 2023 (₩40,284 Mil) to Dec. 2023 (₩33,246 Mil) but then increased from Dec. 2023 (₩33,246 Mil) to Mar. 2024 (₩36,618 Mil).

Medy-Tox's annual Ending Cash Position declined from Dec. 2021 (₩71,777 Mil) to Dec. 2022 (₩20,688 Mil) but then increased from Dec. 2022 (₩20,688 Mil) to Dec. 2023 (₩33,246 Mil).

Medy-Tox Ending Cash Position Historical Data

The historical data trend for Medy-Tox's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medy-Tox Ending Cash Position Chart

Medy-Tox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,016.78 43,993.40 71,777.11 20,688.10 33,246.22

Medy-Tox Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41,185.25 49,014.16 40,284.12 33,246.22 36,617.54

Medy-Tox Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medy-Tox's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=20688.097+12558.126
=33,246

Medy-Tox's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=33246.222+3371.322
=36,618

Medy-Tox Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Medy-Tox's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Medy-Tox (XKRX:086900) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medy-Tox Inc (XKRX:086900) » Definitions » Ending Cash Position
Comparable Companies
XKRX:048410 XKRX:145020 XKRX:214450 XKRX:141080 XKRX:096530 XKRX:085660 XKRX:016790 XKRX:064550 XKRX:298380 XKRX:005250 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
641-4, Gak-Ri, Ochang-Eup, Cheongwon, KOR, 363885
Website
http://www.medytox.com
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Medy-Tox (XKRX:086900) Headlines

No Headlines